Primary Characteristics for the Product
Lucentis belongs to ophthalmic drugs used for people with eye-related problems (mainly related to diabetes-caused issues). The product is created by the NOVARTIS PHARMA, AG manufacturer; it has got its FDA approval fr its effectiveness and exceptional treatment qualities.
The active substance in the composition is ranibizumab (that relates to endothelial growth factor A (VEGF-A)). One package contains 1 pre-filled syringe with the remedy (it should be a transparent, colorless solution), as well as a package insert.
Indications and Dosage
Lucentis injectables are mainly used for the following purposes:
– Neovascular age-related macular degeneration in adults;
– Treat myopic choroidal neovascularization;
– Diabetic retinopathy and diabetic macular edema following retinal vein occlusion;
– Myopic choroidal neovascularization (a condition in which abnormal blood vessels form in a person);
– And so on.
When it comes to treating macular degeneration or dealing with diabetic retinopathy, Lucentis can only be administered into the vitreous body in small portions; only one eye can be treated at a time. The recommended dosage of the remedy is 0.5 mg per month. During the first three months, one administration session per 30 days is needed; after that, the number of treatment sessions can be reduced (however, it can only be done by a medical professional after a careful examination). The product has lower risks of systemic serious adverse events compared to other injectables; that’s why specialists prefer it over other options.
Main Administration Techniques
Before using the Lucentis injection, it is important to have the eye and the area around it disinfected; in this way, it would be easier to reduce the possibility of eye infection afterward. Then, anesthesia is applied along with special antimicrobial drugs (they should also be instilled three days before and after the treatment).
Lucentis is inserted in the zone of the vitreous body 3.5-4 mm behind the limbus, aiming towards the center of the eyeball. It is only possible to have one eye treated at a time.
Some individuals tend to have increased intraocular pressure (IOP) after the injection session, so it is crucial to monitor their well-being to prevent any dangerous conditions that may appear.
Lucentis Side Effects
Healthcare professionals should inform their patients about the following adverse reactions that often occur after the injection session:
– Mild allergic reaction (rash, itching, hives);
– Headache and dizziness;
– Intraocular inflammation, inflammation of the vitreous humor, retinal hemorrhages;
– Eye disorders, irritation, itchy eyes;
– And so on.
Rarely can people catch a cold or flu after the injection session; it can be related to stress or the reaction of the immune system. In case severe side effects, painful sensations, or any other serious problems occur, it is vital to get in touch with a medical professional to receive proper consultation, piece of advice, or treatment plan from a doctor.
Limitations You Should Be Aware Of
Lucentis injections cannot be used for patients with the following health conditions:
– Intraocular inflammation;
– Suspected or confirmed eye infection or irritation in the periorbital area;
– Allergic reaction to ranibizumab;
– Blood clots formation tendency;
– Pregnancy or breastfeeding period in women;
– People before the age of 18.
Please keep in mind that it is essential to be cautious with clients who have a history or increased risk of stroke. Those with arterial thromboembolic complications or a history of transient cerebrovascular accidents should also be careful while using this product.
